Global Human Cytomegalovirus Envelope Glycoprotein B Market Size By Type (CSJ-148, CyMVectin), By Application (Infectious Disease, Oncology), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Cytomegalovirus (HCMV) Envelope Glycoprotein B Market was valued at USD 645 million in 2023 and is projected to surpass USD 1.32 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. The rising prevalence of HCMV infections, increasing R&D efforts focused on vaccine development, and the expansion of biopharmaceutical manufacturing capabilities are key drivers of market growth. Glycoprotein B (gB), a major target antigen for vaccine and diagnostic development due to its critical role in viral entry and cell-to-cell transmission, is increasingly being recognized as a focal point for preventive strategies against congenital HCMV infections and complications in immunocompromised individuals.

Drivers:

1. Rising Global Burden of HCMV:

With high seroprevalence rates in both developing and developed countries, the global impact of HCMV, particularly in neonates and transplant recipients, is substantial. The unmet need for effective vaccines and diagnostic tools based on gB is fueling investment and innovation in this domain.

2. Advancements in Vaccine Development:

The growing pipeline of candidate vaccines targeting HCMV glycoprotein B, including mRNA and subunit-based platforms, is catalyzing market growth. Supportive regulatory frameworks and public-private partnerships are accelerating the translation of R&D into clinical trials.

3. Government & Institutional Support:

Increased funding from healthcare agencies and global health initiatives (such as NIH and WHO) for the prevention of congenital HCMV infections is expected to boost demand for glycoprotein B-based therapeutics and diagnostics.

Restraints:

1. High Cost of Biologic Development:

The development of protein subunit vaccines and biologics centered on glycoprotein B involves complex and costly production processes, which may limit accessibility, especially in low- and middle-income regions.

2. Scientific & Regulatory Challenges:

The absence of a universally accepted surrogate marker for immunity and the slow pace of clinical endpoint establishment are significant bottlenecks that delay the commercialization of HCMV gB-based products.

Opportunity:

1. Emerging Applications in Transplant Medicine:

The growing use of gB-based immunotherapeutics in solid organ and hematopoietic stem cell transplant patients, where HCMV poses a serious threat, opens new revenue streams.

2. Expanding Role in Neonatal Care:

As awareness grows about congenital HCMV infections causing neurodevelopmental delays, the opportunity for gB-based diagnostics and maternal vaccination is expanding, particularly in high-birth-rate countries.

Market by System Type Insights:

Based on product system type, the Vaccine Candidates segment accounted for the largest market share in 2023. The promising results from Phase I and II clinical trials using gB as a key antigen component have drawn robust investment from both pharmaceutical giants and biotech startups. Meanwhile, the Diagnostics segment is projected to grow rapidly due to increasing implementation in prenatal screening and immunocompromised patient monitoring.

Market by End-use Insights:

In 2023, the Biopharmaceutical Companies segment dominated the market owing to active R&D pipelines and large-scale funding. Research Institutions and Academic Centers are anticipated to witness significant growth as collaborations with industry leaders increase to accelerate translational research and preclinical trials.

Market by Regional Insights:

North America led the market in 2023, driven by a strong biotech ecosystem, favorable regulatory pathways, and high awareness of congenital HCMV risks. Europe followed closely due to national immunization priorities and funding in infectious disease prevention. Asia-Pacific is projected to be the fastest-growing region due to improving healthcare infrastructure and increased government focus on maternal and infant health.

Competitive Scenario:

Prominent players in the Global HCMV Envelope Glycoprotein B Market include Moderna Inc., Merck & Co., Hookipa Pharma, VBI Vaccines Inc., Sanofi, and Vir Biotechnology. These firms are actively involved in clinical-stage vaccine development, strategic licensing, and collaborations. For instance:

In 2023, Moderna initiated Phase I trials of its mRNA-based HCMV vaccine targeting gB and pentamer complexes.

VBI Vaccines expanded its partnership with CEPI to advance HCMV vaccine platforms incorporating recombinant glycoprotein B antigens.

In 2024, Hookipa Pharma reported positive preclinical data for its arenavirus-based HCMV vaccine candidate featuring glycoprotein B.

Scope of Work – Global Human Cytomegalovirus Envelope Glycoprotein B Market

Key Market Developments:

June 2023: Moderna commenced a clinical trial for its investigational HCMV vaccine using mRNA-1647, targeting glycoprotein B and pentamer antigens.

October 2023: VBI Vaccines entered a co-development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) for HCMV vaccine acceleration.

January 2024: Merck & Co. announced results from a Phase II study showing enhanced neutralizing antibody response using a gB-based subunit vaccine in transplant recipients.

FAQs:

1. What is the current market size of the Global Human Cytomegalovirus Envelope Glycoprotein B Market?

The market was valued at USD 645 million in 2023.

2. What is the major growth driver of the Global Human Cytomegalovirus Envelope Glycoprotein B Market?

The primary growth driver is the increasing global burden of HCMV and intensified efforts in vaccine development targeting glycoprotein B.

3. Which is the largest region during the forecast period in the Global Human Cytomegalovirus Envelope Glycoprotein B Market?

North America is expected to remain the largest regional market due to its advanced healthcare infrastructure and R&D investment.

4. Which segment accounted for the largest market share in the Global Human Cytomegalovirus Envelope Glycoprotein B Market?

The Vaccine Candidates segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Human Cytomegalovirus Envelope Glycoprotein B Market?

Major players include Moderna Inc., Merck & Co., Hookipa Pharma, VBI Vaccines Inc., Sanofi, and Vir Biotechnology.